Swedish Orphan Biovitrum
Tracked across 4 events · 28 articles · First seen Apr 09, 2026 · Last active Aug 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Swedish Orphan Biovitrum announced positive topline results from its pivotal Phase 3 REDUCE 2 study for pozdeutinurad, which is expected to significantly enhance its presence in the gout treatment market and potentially boost its stock value.
May 21, 2026 · 6 articles
Regulatory
Impact: Swedish Orphan Biovitrum received a Complete Response Letter from the FDA for its Biologics License Application for National Association of Securities Professionals, requiring additional data and addressing facility deficiencies. This delays the approval process for their drug.
Jun 26, 2026 · 6 articles
Business
Impact: Sobi is the licensee and will pay $75 million upfront, gaining exclusive global commercialization rights to lacutamab. This strengthens its rare disease portfolio and provides growth potential.
Aug 10, 2026 · 10 articles
Tech
Impact: Swedish Orphan Biovitrum is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.
Apr 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Swedish Orphan Biovitrum live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard